| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML006 | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | KIN001-236 | GDSC1000 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | KIN001-270 | GDSC1000 | pan-cancer | AAC | 0.0025 | 0.9 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | MS-275 | GDSC1000 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | ATRA | GDSC1000 | pan-cancer | AAC | -0.0024 | 0.9 |
| mRNA | XMD13-2 | GDSC1000 | pan-cancer | AAC | 0.0022 | 0.9 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | 0.0035 | 0.9 |